Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03882970 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,444
- Enrollment target
NCT03882970 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,444 participants.
The verdict
NCT03882970, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,444 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
Interventions
- DRUG Tirzepatide
- DRUG Insulin Degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,444 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-01-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03882970
The ClinicalTrials.gov registry entry for NCT03882970 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT03882970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03882970 about?
NCT03882970 is a clinical study titled "A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes". The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
What is the current status of trial NCT03882970?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,444 participants. The study started on 2019-04-01. Estimated completion is 2021-01-04.
What interventions are being tested in trial NCT03882970?
The interventions under investigation include: Tirzepatide (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT03882970?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.